$VKTX
Viking Therapeutics, Inc.
Runway:3 mo
NasdaqMarket cap: —CIK 0001607678
Insider signals· last 90 days
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| 2026-03-10 | Aubuchon Neil WilliamChief Commercial Officer | 4,475 | $33.50 | $0.15M |
Upcoming catalysts
0 surfacedNo catalysts surfaced for VKTX yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07104383 | VK2735 | Phase 3 | Active Not Recruiting | 2027-07-01 |
| NCT07104500 | VK2735 | Phase 3 | Active Not Recruiting | 2027-07-01 |
| NCT06828055 | Placebo | Phase 2 | Completed | 2025-06-24 |
| NCT05203237 | VK2735 | Phase 1 | Completed | 2024-11-04 |
| NCT04973657 | VK0214 | Phase 1 | Completed | 2024-10-09 |
| NCT06068946 | VK2735 | Phase 2 | Completed | 2024-02-27 |
| NCT04173065 | VK2809 | Phase 2 | Completed | 2023-05-15 |
| NCT02927184 | VK2809 | Phase 2 | Completed | 2019-03-26 |
| NCT02578095 | VK5211 | Phase 2 | Completed | 2017-11-15 |